GCM
MLTX icon

Graham Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Graham Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419K Buy
21,545
+456
+2% +$8.27K 0.01% 774
2026
Q1 		$393K Sell
21,089
-3,203
-13% -$53.1K 0.01% 709
2025
Q4 		$320K Buy
+24,292
New +$287K 0.01% 830
2023
Q4 		– Sell
-4,352
Closed -$248K – 1198
2023
Q3 		$248K Buy
+4,352
New +$240K 0.01% 787

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Graham Capital Management's MLTX Position: Q2 2026 in Review

Graham Capital Management increased its MoonLake Immunotherapeutics (MLTX) stake by 2.2% in Q2 2026, buying an estimated $8.27K and bringing the position to 21,545 shares worth $419K. The position accounts for 0.01% of the portfolio, ranked #774.

Graham Capital Management first reported a position in MLTX in Q3 2023 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Graham Capital Management held 21,545 shares of MoonLake Immunotherapeutics worth $419K as of Q2 2026.
  • Graham Capital Management bought 456 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $8.27K.
  • MoonLake Immunotherapeutics made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #774 holding.
  • Graham Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.